Quidel Co. (NASDAQ:QDEL) VP Sells $743,080.00 in Stock

Quidel Co. (NASDAQ:QDEL) VP Edward Keith Russell sold 13,000 shares of Quidel stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $57.16, for a total value of $743,080.00. Following the sale, the vice president now directly owns 18,401 shares of the company’s stock, valued at approximately $1,051,801.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Edward Keith Russell also recently made the following trade(s):

  • On Thursday, March 28th, Edward Keith Russell sold 13,000 shares of Quidel stock. The stock was sold at an average price of $64.60, for a total value of $839,800.00.

Shares of QDEL traded down $0.38 during mid-day trading on Friday, reaching $57.35. The company’s stock had a trading volume of 129,480 shares, compared to its average volume of 176,062. The firm’s 50 day moving average price is $57.19. The firm has a market capitalization of $2.30 billion, a PE ratio of 20.34, a PEG ratio of 0.85 and a beta of 1.36. The company has a current ratio of 1.33, a quick ratio of 0.91 and a debt-to-equity ratio of 0.25. Quidel Co. has a 12-month low of $44.27 and a 12-month high of $77.63.

Quidel (NASDAQ:QDEL) last released its quarterly earnings results on Wednesday, May 8th. The company reported $0.84 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.98 by ($0.14). The firm had revenue of $148.00 million for the quarter, compared to analysts’ expectations of $157.61 million. Quidel had a return on equity of 25.33% and a net margin of 12.98%. The company’s quarterly revenue was down 12.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.29 EPS. Sell-side analysts forecast that Quidel Co. will post 2.72 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. lifted its stake in shares of Quidel by 0.6% in the fourth quarter. BlackRock Inc. now owns 2,304,494 shares of the company’s stock valued at $112,504,000 after buying an additional 12,840 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Quidel by 2.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 861,159 shares of the company’s stock worth $42,041,000 after purchasing an additional 17,041 shares during the period. Norges Bank acquired a new stake in shares of Quidel during the fourth quarter worth about $34,899,000. Eagle Asset Management Inc. lifted its holdings in shares of Quidel by 1.4% during the first quarter. Eagle Asset Management Inc. now owns 639,841 shares of the company’s stock worth $41,890,000 after purchasing an additional 8,939 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Quidel by 22.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 407,887 shares of the company’s stock worth $19,913,000 after purchasing an additional 74,284 shares during the period. 91.40% of the stock is owned by institutional investors and hedge funds.

Several brokerages recently commented on QDEL. Raymond James reiterated an “average” rating and set a $23.00 price target on shares of in a research report on Monday, April 15th. ValuEngine cut Intersect ENT from a “buy” rating to a “hold” rating in a report on Monday, July 8th. Canaccord Genuity restated a “speculative buy” rating and issued a GBX 70 ($0.91) target price on shares of Bacanora Lithium in a report on Monday, July 1st. Barclays reiterated a “buy” rating and set a $304.00 price target on shares of Adobe in a report on Monday, March 18th. Finally, BidaskClub cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, three have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Quidel presently has an average rating of “Buy” and an average target price of $71.17.

Quidel Company Profile

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.

Featured Article: Why is cost of goods sold important?

Insider Buying and Selling by Quarter for Quidel (NASDAQ:QDEL)

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.